{"product_id":"gh-ansoff-analysis","title":"(GH) Guardant Health, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Guardant Health, Inc. Ansoff Matrix Analysis summarizes the company’s growth options across market penetration, market development, product development, and diversification in a concise, actionable matrix; it’s used for strategy, investment, or planning and this page already contains a real preview of the analysis so you can judge style and substance. Purchase the full version to receive the complete, ready-to-use Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExpand Guardant360 adoption in advanced-stage cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant360 is Guardant Health, Inc.’s flagship liquid biopsy for advanced-stage cancer, offered as both LDT and CDx, so the market penetration move is to win more use in the same oncology base. In 2025, this matters most in metastatic solid tumors, where faster biomarker results can steer therapy without another tissue draw. Deeper adoption in U.S. and international precision oncology workflows should lift test volume and share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGrow GuardantOMNI usage for broad genomic profiling\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardantOMNI already sits in Guardant Health, Inc.’s advanced cancer portfolio, so this is classic market penetration: sell more of the same test to the same user base. In 2025-2026, the focus is on oncologists and biopharma teams that need broad blood-based genomic profiling for treatment selection and trial matching. \u003c\/p\u003e\n\u003cp\u003eThe lever is share expansion, not a new market. More orders should come from deeper lab-to-clinic adoption, stronger physician familiarity, and repeat use in advanced solid tumors. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIncrease Guardant Reveal use in early-stage treatment decisions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Reveal is already used in early-stage colon cancer to help guide neoadjuvant and adjuvant treatment choices, so market penetration means making that same test a routine part of more oncology workflows. Guardant Health reported 2025 revenue growth in its liquid biopsy franchise, showing room to expand use without changing the product. Wider adoption in current care settings can lift test volume, repeat ordering, and clinical stickiness.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMonetize GuardantINFORM with deeper biopharma adoption\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardantINFORM can drive market penetration by selling more analyses and broader dataset access to the same biopharma and research accounts. It uses Guardant Health's clinical-genomic liquid biopsy data for in-silico research, so the growth path is share gain in an existing analytics market, not a new market bet.\u003c\/p\u003e\n\u003cp\u003eEach added project can lift wallet share with low incremental data-cost, since the core asset is already built. The key move is deeper use inside current customers, especially teams running translational research, biomarker work, and target validation.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSell more analyses to current buyers\u003c\/li\u003e\n\u003cli\u003eExpand access to one dataset\u003c\/li\u003e\n\u003cli\u003eRaise share in analytics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExpand existing development services with current biopharma and medical clients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health can deepen market penetration by selling more of the same 5 services to existing biopharma and medical clients. That lifts wallet share without changing the core offer, so revenue can grow with lower sales friction and no new service line risk.\u003c\/p\u003e\n\u003cp\u003eThis fits the Ansoff Matrix's market penetration play: keep the customer base, expand use of companion diagnostic development, regulatory support, clinical study management, testing development, and kit fulfillment. It is the fastest path to more revenue per client, especially where development programs already span multiple phases.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e5 current services already support expansion\u003c\/li\u003e\n\u003cli\u003eFocus on higher wallet share\u003c\/li\u003e\n\u003cli\u003eGrow revenue without new service scope\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant Health Deepens Oncology Wallet Share\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc. is using market penetration to push Guardant360, GuardantOMNI, Reveal, and INFORM deeper into existing oncology and biopharma accounts. The play is more test volume, more repeat use, and more wallet share in 2025-2026, with growth coming from the same customer base, not new products or new markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCurrent offer\u003c\/th\u003e\n\u003cth\u003ePenetration move\u003c\/th\u003e\n\u003cth\u003e2025-2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardant360\u003c\/td\u003e\n\u003ctd\u003eMore use in metastatic solid tumors\u003c\/td\u003e\n\u003ctd\u003eLiquid biopsy franchise grew in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardantOMNI\u003c\/td\u003e\n\u003ctd\u003eMore orders from current oncology users\u003c\/td\u003e\n\u003ctd\u003eBroad profiling and trial matching\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardant Reveal\u003c\/td\u003e\n\u003ctd\u003eRoutine use in early-stage colon cancer\u003c\/td\u003e\n\u003ctd\u003eRepeat workflow adoption\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eINFORM\u003c\/td\u003e\n\u003ctd\u003eMore analyses for same biopharma clients\u003c\/td\u003e\n\u003ctd\u003eHigher dataset wallet share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear Ansoff Matrix framework for analyzing Guardant Health, Inc.’s growth strategy across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Guardant Health Ansoff Matrix to simplify growth planning across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites authoritative Guardant Health filings, presentations, and peer-reviewed studies to fast-verify Ansoff Matrix growth paths with traceable, decision-grade sources.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtend Guardant360 beyond the core U.S. oncology base\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health already sells Guardant360 in the U.S. and select international markets, so market development means pushing the same assay into more geographies and care settings. That widens the addressable base without changing the product, and each new payer or hospital contract can lift volume fast. Guardant360 CDx already supports multiple biomarker uses, so the growth lever is access, not redesign.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBroaden GuardantOMNI international reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardantOMNI is an existing liquid biopsy test, so the Ansoff play is market development: sell the same product into new countries and hospital systems that are not yet full users. Global cancer burden stays large, with about 20 million new cases a year, so even modest international uptake can add volume without changing the test itself. Guardant Health can grow by expanding reimbursement, local approvals, and partner labs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eScale Guardant Reveal into more early-stage cancer centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Reveal is already used for early-stage cancer treatment selection, so market development here means placing the same assay in more cancer centers and clinical networks. That expands access, not the product line. This is a classic Ansoff move: more institutions, same test, same clinical use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTake GuardantINFORM to additional research and pharma segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardantINFORM can move from a single oncology use case into broader research and pharma buyers that need real-world evidence and in-silico tools. It draws on Guardant Health’s large liquid biopsy dataset from advanced cancer patients, which gives pharma teams faster hypothesis testing, cohort finding, and biomarker work without starting from zero.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting platform, new buyer segments\u003c\/li\u003e\n\u003cli\u003eUses real-world clinical-genomic data\u003c\/li\u003e\n\u003cli\u003eFits pharma and research workflows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eUse Guardant360 tissue genotyping in new clinical workflows\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health can push Guardant360 tissue genotyping into more pathology and oncology workflows that still use legacy tissue tests. The product is already built, so the market move is about adoption, not invention, and that can widen revenue without a new launch. It fits labs that want faster, more standardized NGS-based tissue profiling.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpand into new lab workflows\u003c\/li\u003e\n\u003cli\u003eReplace older tissue methods\u003c\/li\u003e\n\u003cli\u003eGrow footprint, not product line\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant Health Scales Global Cancer Testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health’s market development is selling the same assays into more countries, hospitals, and payer-covered workflows. Guardant360, Reveal, and OMNI can scale without redesign, and the global cancer burden of about 20 million new cases a year keeps the addressable market large.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLever\u003c\/th\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardant360\u003c\/td\u003e\n\u003ctd\u003eNew geographies\u003c\/td\u003e\n\u003ctd\u003e20M new cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReveal\u003c\/td\u003e\n\u003ctd\u003eMore cancer centers\u003c\/td\u003e\n\u003ctd\u003eSame assay\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOMNI\u003c\/td\u003e\n\u003ctd\u003eNew hospital systems\u003c\/td\u003e\n\u003ctd\u003eSame platform\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eGuardant Health, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvance LUNAR-2 for early colorectal cancer detection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc. is using LUNAR-2 to move into early colorectal cancer detection in asymptomatic people, a new clinical use that fits product development in the Ansoff Matrix. The test expands beyond the company’s advanced-cancer base and targets a much larger screening market; colorectal cancer caused about 1.9 million new cases and 900,000 deaths worldwide in 2022.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBuild GuardantConnect as a trial-matching software platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardantConnect fits product development: it adds a new software layer on top of Guardant360, turning a single test into a trial-matching tool for biopharma and clinics. Guardant360 CDx profiles 739 genomic alterations across 74 genes, so the platform can match patients to studies faster and deepen use of existing data. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhance Guardant Reveal for earlier-stage treatment guidance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Reveal already supports neoadjuvant and adjuvant treatment selection in early-stage cancer, and this move deepens that same use case instead of chasing a new market. In the U.S., about 1.9 million new cancer cases were projected for 2025, so even small gains in earlier decision support can matter. This strengthens Guardant Health, Inc.'s treatment-guidance portfolio around one of its highest-value clinical workflows.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExpand Guardant360 into tissue genotyping\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health, Inc. can extend Guardant360 from liquid biopsy into tissue genotyping as a product extension, not a new market play. In the U.S., the American Cancer Society projected 2,041,910 new cancer cases in 2025, so one brand that works across blood and tissue can fit more oncology workflows and keep more testing inside the same care path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame cancer-care customers\u003c\/li\u003e\n\u003cli\u003eNew testing format, same brand\u003c\/li\u003e\n\u003cli\u003eBroader use across oncology workflows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLeverage GuardantINFORM as a broader analytical product\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardantINFORM pushes Guardant Health, Inc. beyond test sales by turning its liquid biopsy data into an in-silico research platform. That is product development in practice: add analytics, deeper insights, and more software value on top of the same data asset. It also shifts the mix toward higher-margin, recurring data and software revenue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands GuardantINFORM beyond raw data access\u003c\/li\u003e\n\u003cli\u003eAdds software-style analytical features\u003c\/li\u003e\n\u003cli\u003eSupports a more data-led revenue mix\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant Health Expands Oncology Reach With New Tests and Software\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health, Inc. is using product development to widen its same oncology base with new tests, software, and use cases. LUNAR-2 targets early colorectal screening; GuardantConnect adds trial-matching to Guardant360; Reveal expands treatment guidance; and GuardantINFORM adds analytics. 2025 U.S. cancer cases were projected at 2,041,910.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct move\u003c\/th\u003e\n\u003cth\u003e2025-2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLUNAR-2\u003c\/td\u003e\n\u003ctd\u003eEarly CRC screening\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardantConnect\u003c\/td\u003e\n\u003ctd\u003eTrial matching\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReveal\u003c\/td\u003e\n\u003ctd\u003eEarlier treatment use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardantINFORM\u003c\/td\u003e\n\u003ctd\u003eData and software\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnter infectious disease testing with Guardant-19\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant-19, cleared by the FDA in 2020 for SARS-CoV-2 detection, moved Guardant Health from oncology into a new infectious-disease market with a new diagnostic product. That is classic diversification in the Ansoff Matrix: new product, new market. It also showed how fast the company could pivot beyond liquid biopsy.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eServe biopharma with companion diagnostic development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health’s companion diagnostic development for biopharma is diversification: it targets drug makers, not routine patient testing, and sells a service model instead of a standard assay. This is a new market and a new offer, so it can widen revenue beyond clinical testing. Biopharma R\u0026amp;D spend is now in the hundreds of billions of dollars globally, which keeps demand for companion diagnostics strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOffer regulatory approval support to external partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGuardant Health already serves biopharma and clinical clients, and that non-core work broadens revenue beyond diagnostics. With 2024 revenue near $760 million, it has the scale to sell specialized regulatory approval support as a services line. That makes this a true diversification move built on regulatory expertise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManage clinical studies for external customers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health, Inc. is diversifying beyond blood tests by managing clinical studies for external medical and biopharma clients, including study setup, monitoring, and maintenance. That moves the company into trial-operations services, a different market with recurring service revenue and deeper client ties. It also broadens demand beyond test sales alone.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExternal trial services\u003c\/li\u003e\n\u003cli\u003eSetup, monitoring, maintenance\u003c\/li\u003e\n\u003cli\u003eNew biopharma customer base\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDeliver testing development and kit fulfillment services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGuardant Health’s testing development and kit fulfillment services move it beyond end-patient diagnostics into adjacent healthcare operations. In FY2024, the Company generated about $759 million in revenue, so these services add a smaller but strategic revenue layer that can deepen partner ties and use existing lab and logistics assets.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAdjacent services, not just diagnostics\u003c\/li\u003e\n\u003cli\u003eSupports external healthcare partners\u003c\/li\u003e\n\u003cli\u003eUses existing lab and fulfillment capacity\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGuardant Health Expands Beyond Oncology Into New Growth Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGuardant Health’s diversification is real: it has moved from oncology testing into Guardant-19, biopharma companion diagnostics, trial services, and kit fulfillment. These are new products in new markets, so they fit the Ansoff diversification bucket. FY2024 revenue was about $759 million, showing the base to support these moves.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2024 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGuardant-19\u003c\/td\u003e\n\u003ctd\u003eFDA-cleared in 2020\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003eAbout $759 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234409324809,"sku":"gh-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/gh-ansoff-matrix.webp?v=1785719837","url":"https:\/\/dcfanalyst.com\/products\/gh-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}